You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeted Epigenetic Therapy for Triple-Negative Breast Cancer

    SBC: PARKSIDE SCIENTIFIC INC.            Topic: 102

    DESCRIPTIONprovided by applicantTriple negative breast cancerTNBCis one of the most aggressive forms of human cancerand currently has no targeted therapyChemotherapy is the only available treatment for TNBC patientsbut is deleterious and not effective once tumor spreadsTNBC represents a major unmet medical needaboutof breast cancer incidenceswomen worldwide inare TNBCTNBC disproportionally affects ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. DR?1-MOG as a Next-Generation Immunotherapy for Methamphetamine Use Disorder

    SBC: VIROGENOMICS BIODEVELOPMENT INC            Topic: R41

    Methamphetamine use disorder is associated with damage to regions of the brain that control cognitive and psychiatric functionOne third to one half of adults with methamphetamine use disorder experience cognitive impairments and other psychiatric symptoms that significantly impact treatment outcomesincreased relapse and lower treatment retention ratesMounting evidence demonstrates how immune facto ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen

    SBC: Arrevus, Inc.            Topic: NIAID

    Multi drug resistantMDRbacterial infections represent a significant threat to public healthIt is estimated that the impact of antibiotic resistance will continue to grow resulting in a global economic burden of $trillion and causingmillion deaths annuallyMany of the therapeutics currently under development represent traditional antibiotic approaches or next generation antibiotics that will likely ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. MtLDL detection to diagnose childhood tuberculosis

    SBC: CHRONUS PHARMACEUTICALS, INC.            Topic: NIAID

    Project SummaryChildhood TB is estimated to contributeof the disease burden in high burden settingswith approximately a million cases per year inworldwideExisting gold standard diagnostic culture tools fail to confirm TB in most childrenwho typically have low bacterial counts and cannot produce sputumMore sensitive and child friendly diagnostic tools are urgently needed to diagnose TB in childrenC ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Astrocyte activation by small-molecule ADORA3 agonists: a novel therapy for Alzheimer's disease

    SBC: ASTROCYTE PHARMACEUTICALS INC.            Topic: NIA

    PROJECT SUMMARY Alzheimerandapos s diseaseADis an area of significant unmet need that creates a national burden of$billion annuallyAD is the leading cause of dementiaaffectingof Americans over the age ofDemographic shifts and the age related nature of AD will soon place this disease as the costliest health care expenditure in the U Swith a projected impact of $trillion per year byCurrent therapies ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia

    SBC: Arrevus, Inc.            Topic: NIAID

    Bloodstream infectionsBSIscaused by Gram negative bacterial pathogens are associated with significant morbidity and mortality due to the antibiotic resistant nature of the pathogensInfections caused by multi drug resistantMDRbacterial pathogens result in substantial health and economic impact due to the lack of effective therapeutic optionsThis lack of treatment options is particularly relevant fo ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Multimodality image-based assessment system for traumatic brain injury

    SBC: KITWARE INC            Topic: NINDS

    DESCRIPTION (provided by applicant): Nearly 1.7 million Americans suffer traumatic brain injury (TBI) annually, which constitutes an important and significant US medical health concern. Although neuroimaging plays an important role in pathology localization and surgical planning, TBI clinical care does not currently take full advantage of neuroimaging computational technology. We propose to develo ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Mitochondrial TAT-DNA repair proteins for treatment of insulin resistance

    SBC: EXSCIEN CORPORATION            Topic: NIDDK

    DESCRIPTION provided by applicant Insulin resistance IR also known as metabolic syndrome is tied to obesity and is associated with numerous modern health problems including the growing problems of type diabetes and cardiovascular disease The growing health economic and social burdens of these conditions calls for the need to develop drug treatments for IR We know from multiple lines of ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Integration of Immunochemical, Genomic and Transcriptomic Analyses of Human Skin

    SBC: INTEGRATED TISSUE DYNAMICS LLC            Topic: NINDS

    DESCRIPTION (provided by applicant): Wide varieties of peripheral neuropathies accompanied by severe chronic pain are among the most common and debilitating human afflictions. Existing treatments have little long term benefits and often have severe side effects. Increasing evidence indicates that pathologies in the structure and chemistry of the skin and its innervation are likely contributors to ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections

    SBC: Arrevus, Inc.            Topic: NIAID

    Urinary tract infectionsUTIsare one of the most common hospital acquired infections and are often caused by multi drug resistantMDRbacterial pathogensMDR bacterial pathogens are associated with significant morbidity and mortalitycreating enormous healthcare and economic burdens due to variations in disease natural histories as well as the lack of effective therapeutic optionsTreatment option limit ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government